Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;44(6):2730-2773.
doi: 10.1002/med.22059. Epub 2024 Jun 17.

Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future

Victoria Judith Morel  1   2 , Jochen Rössler  1   2 , Michele Bernasconi  1   2
Affiliations
Free article
Review

Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future

Victoria Judith Morel et al. Med Res Rev. 2024 Nov.
Free article

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Histology separates two main subtypes: embryonal RMS (eRMS; 60%-70%) and alveolar RMS (aRMS; 20%-30%). The aggressive aRMS carry one of two characteristic chromosomal translocations that result in the expression of a PAX3::FOXO1 or PAX7::FOXO1 fusion transcription factor; therefore, aRMS are now classified as fusion-positive (FP) RMS. Embryonal RMS have a better prognosis and are clinically indistinguishable from fusion-negative (FN) RMS. Next to histology and molecular characteristics, RMS risk groupings are now available defining low risk tumors with excellent outcomes and advanced stage disease with poor prognosis, with an overall survival of about only 20% despite intensified multimodal treatment. Therefore, development of novel effective targeted strategies to increase survival and to decrease long-term side effects is urgently needed. Recently, immunotherapies and nanomedicine have been emerging for potent and effective tumor treatments with minimal side effects, raising hopes for effective and safe cures for RMS patients. This review aims to describe the most relevant preclinical and clinical studies in immunotherapy and targeted nanomedicine performed so far in RMS and to provide an insight in future developments.

Keywords: immunotherapy; nanomedicine; nano‐immunomedicine; rhabdomyosarcoma; targeted therapy.

PubMed Disclaimer

References

REFERENCES

    1. Williams RF, Fernandez‐Pineda I, Gosain A. Pediatric sarcomas. Surg Clin North Am. 2016;96(5):1107‐1125. doi:10.1016/j.suc.2016.05.012
    1. Hatley ME, Tang W, Garcia MR, et al. A mouse model of rhabdomyosarcoma originating from the adipocyte lineage. Cancer Cell. 2012;22(4):536‐546. doi:10.1016/j.ccr.2012.09.004
    1. Martin‐Giacalone BA, Weinstein PA, Plon SE, Lupo PJ. Pediatric rhabdomyosarcoma: epidemiology and genetic susceptibility. J Clin Med. 2021;10(9):2028. doi:10.3390/jcm10092028
    1. Fletcher CDM, Baldini EH, Blay JY, et al. WHO Classification of Tumours. Soft Tissue and Bone Tumours. Vol 5. IARC Press; 2020:201‐215.
    1. Barr FG, Smith LM, Lynch JC, et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the intergroup rhabdomyosarcoma study‐III trial. J Mol Diagn. 2006;8(2):202‐208. doi:10.2353/jmoldx.2006.050124

Publication types